

| Catalog No. | HF737016 |
|---|---|
| Species reactivity | Human |
| Applications | ELISA, Functional assay, Research in vivo |
| Isotype | Synthetic glucagon peptide analogue conjugated with human IgG4 Fc fragment |
| Biological activity | GLP-1 (7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats [2]. Infusion of GLP-1 (7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM [2]. |
| Expression system | Mammalian cells |
| Target | GLP-1(7-36), Incretin hormone, GLP-2, GCG, GLP-1(7-37), OXM, Pro-glucagon, GLP-1, GRPP, OXY |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P01275 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | 2766774-81-4 |
| Background | Pro-glucagon (GCG) is a ~20 kDa protein. Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Binds to and activates the glucagon receptor GCGR, which couples to the G(s) G protein and elevates intracellular cAMP, triggering downstream metabolic responses. 1. Qiao, A. et al. (2020) Science (New York, N.Y.) 367, 1346-1352. PMID: 32193322 |
| References | 1. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004). [HF737016] 2. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7. [HF737016] |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com
+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский